Evidence map›Paper›PMID 23288365›Full record

ArticleMolecular neurobiology2013

Direct GSK-3β inhibition enhances mesenchymal stromal cell migration by increasing expression of β-PIX and CXCR4.

Young Seo Kim, Min Young Noh, Ji Young Kim, Hyun-Jeung Yu, Kyung Suk Kim, Seung Hyun Kim, Seong-Ho Koh

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Cell augmentation strategies for cardiac stem cell therapies.Stem cells translational medicine · 2021
    Review
  6. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [Diagnostics (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. MicroRNAs in the Migration of Mesenchymal Stem Cells.Stem cell reviews and reports · 2019
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Young Seo KimDepartment of Neurology, College of Medicine, Hanyang University, 249-1 Gyomun-dong, Guri-si, Seoul, Gyeonggi-do 471-701, Republic of Korea.
Min Young Noh
Ji Young Kim
Hyun-Jeung Yu
Kyung Suk Kim
Seung Hyun Kim
Seong-Ho Koh
Hanyang University · KRBundang Jesaeng Hospital · KRCorestem (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are emerging as candidate cells for the treatment of neurological diseases because of their neural replacement, neuroprotective, and neurotrophic effects. However, the majority of MSCs transplanted by various routes fail to reach the site of injury, and they have demonstrated only minimal therapeutic benefit in clinical trials. Therefore, enhancing the migration of MSCs to target sites is essential for this therapeutic strategy to be effective. In this study, we assessed whether inhibition of glycogen synthase kinase-3β (GSK-3β) increases the migration capacity of MSCs during ex vivo expansion. Human bone marrow MSCs (hBM-MSCs) were cultured with various GSK-3β inhibitors (LiCl, SB-415286, and AR-A014418). Using a migration assay kit, we found that the motility of hBM-MSCs was significantly enhanced by GSK-3β inhibition. Western blot analysis revealed increased levels of migration-related signaling proteins such as phospho-GSK-3β, β-catenin, phospho-c-Raf, phospho-extracellular signal-regulated kinase (ERK), phospho-β-PAK-interacting exchange factor (PIX), and CXC chemokine receptor 4 (CXCR4). In addition, real-time polymerase chain reaction demonstrated increased expression of matrix metalloproteinase-2 (MMP-2), membrane-type MMP-1 (MT1-MMP), and β-PIX. In the reverse approach, treatment with β-PIX shRNA or CXCR4 inhibitor (AMD 3100) reduced hBM-MSC migration. These findings suggest that inhibition of GSK-3β during ex vivo expansion of hBM-MSCs may enhance their migration capacity by increasing expression of β-catenin, phospho-c-Raf, phospho-ERK, and β-PIX and the subsequent up-regulation of CXCR4. Enhancing the migration capacity of hBM-MSCs by treating these cells with GSK-3β inhibitors may increase their therapeutic potential.

Indexed as

Cell MovementCell ProliferationCells, CulturedCell SurvivalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansMesenchymal Stem CellsProtein Kinase InhibitorsReceptors, CXCR4Rho Guanine Nucleotide Exchange FactorsUp-RegulationARHGEF7 protein, humanCXCR4 protein, humanGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanProtein Kinase InhibitorsReceptors, CXCR4Rho Guanine Nucleotide Exchange Factors

Identifiers

PMID23288365
OpenAlexW1983966397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.